Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles Sawyers, Francois Guilhot, Charles A. Schiffer, Jorge Cortes, Dietger W. Niederwieser, Carlo Gambacorti, Richard M. Stone, John Goldman, Thomas Fischer, Stephen G. O'Brien, Jose J. Reiffers, Manisha Mone, Tillmann Krahnke, Moshe Talpaz, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

200 Scopus citations

Fingerprint

Dive into the research topics of 'Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds